Compass Therapeutics on Track for Q1 2026 Tovecimig Survival Analyses, Expands CTX-8371 Cohorts
Compass Therapeutics reported that key survival analyses of progression-free and overall survival for its Phase 2/3 COMPANION-002 study of tovecimig in advanced biliary tract cancer remain on track for late Q1 2026, supported by an estimated $209 million cash runway into 2028. In its Phase 1 CTX-8371 program, a third confirmed Hodgkin lymphoma response and durable deep partial response in TNBC through week 32 have prompted cohort expansions in TNBC and NSCLC, and a Phase 1 trial of CTX-10726 is slated to initiate in Q1 2026.
1. Late Q1 2026 PFS and OS Data Readouts
Compass Therapeutics remains on schedule to report key progression-free survival (PFS) and overall survival (OS) analyses from its Phase 2/3 COMPANION-002 study of tovecimig in advanced biliary tract cancer (BTC) in late Q1 2026. These analyses represent the trial’s co–primary endpoints and will inform potential accelerated approval discussions. The randomized study enrolled over 250 patients across North America and Europe, all of whom had failed at least one line of systemic therapy, and is powered to detect a 35% reduction in risk of progression or death with tovecimig versus standard of care.
2. CTX-8371 Confirms Third Hodgkin Lymphoma Response and Expands Cohorts
In its ongoing Phase 1 dose-escalation trial, Compass has confirmed a third objective response to CTX-8371—a PD-1 × PD-L1 bispecific antibody—in a patient with relapsed Hodgkin lymphoma following checkpoint inhibitor failure. CTX-8371 has now demonstrated durable responses in both hematologic and solid tumors, including a deep partial response in triple-negative breast cancer that persists through week 32. Based on these data, Compass has opened cohort expansions in triple-negative breast cancer and non-small cell lung cancer, each enrolling up to 28 patients at two dose levels (3.0 and 10.0 mg/kg) in the post-checkpoint inhibitor setting, with initial data expected in H1 2026.
3. CTX-10726 Phase 1 Study Initiation Expected in Q1 2026
Compass plans to initiate the first-in-human Phase 1 dose-escalation trial of CTX-10726, a PD-1 × VEGF-A bispecific antibody, in Q1 2026. Preclinical head-to-head xenograft and in vitro studies demonstrated superior tumor control versus comparator antibodies and enhanced PD-1 blockade, supporting the molecule’s potential for improved efficacy. Initial safety, pharmacokinetic, and early efficacy data are anticipated in H2 2026.
4. Strong Cash Position Provides Runway into 2028
As of December 31, 2025, Compass reported approximately $209 million in cash and marketable securities, sufficient to fund operations and planned clinical programs through at least 2028. This liquidity supports the company’s multiple upcoming milestones, including the tovecimig survival analyses, CTX-8371 expansion data, first CTX-10726 readouts, and preparation for potential tovecimig BLA filing.